Skip to main content


Immunic AG is headquartered in Germany from where overseeing an expansion to Australia to conduct clinical trials was daunting.
  • Client industry:
    Life sciences
  • Services:
    Company registration
  • Country:

The challenge

Immunic was interested in conducting clinical trials in Australia, but they needed support to manage this expansion and to administer an Australian subsidiary in line with local tax regulations and law. They also needed guidance to find key local partners to get their clinical trial up and running.

Acclime was recommended to us by several German biotech companies. We have been very pleased with how easy they have made it to estabish and administer our Australian subsidiary.

Immunic’s needs

  • Advice on structuring and registration of the Australian entity
  • Completed company registrations with full compliance, licensing and transparency
  • Tax advice on investment incentives
  • Ongoing compliance and reporting support

Our solution

With several recommendations from other German biotech companies, Immunic chose to partner with Acclime. Our team of tax, finance and compliance specialists made the whole process easy, with seamless support through the initial company incorporation process, to identifying key partners, to the ongoing management of Immunic’s Australian subsidiary.

 The whole process has run smoothly. Our Phase 1 trials commenced successfully late in 2019, and we look forward to working with CoSec into the future.

Erika von der Decken
Immunic AG

The result

Immunic commenced Phase 1 of its clinical trials in Australia in September 2019.

About Immunic

Immunic is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic AG in Germany wanted to expand to Australia and undertake clinical trials.